|
1
|
American Diabetes Association: Diagnosis
and classification of diabetes mellitus. Diabetes Care. 37 (Suppl
1):S81–S90. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jarmuzek P, Wielgos M and Bomba-Opon D:
Placental pathologic changes in gestational diabetes mellitus.
Neuro Endocrinol Lett. 36:101–105. 2015.PubMed/NCBI
|
|
3
|
Aires MB and Dos Santos AC: Effects of
maternal diabetes on trophoblast cells. World J Diabetes.
6:338–344. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sibley CP, Brownbill P, Glazier JD and
Greenwood SL: Knowledge needed about the exchange physiology of the
placenta. Placenta. 64 (Suppl 1):S9–S15. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leach L, Lammiman MJ, Babawale MO, Hobson
SA, Bromilou B, Lovat S and Simmonds MJ: Molecular organization of
tight and adherens junctions in the human placental vascular tree.
Placenta. 21:547–557. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leach L, Taylor A and Sciota F: Vascular
dysfunction in the diabetic placenta: Causes and consequences. J
Anat. 215:69–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sobrevia L, Salsoso R, Fuenzalida B,
Barros E, Toledo L, Silva L, Pizarro C, Subiabre M, Villalobos R,
Araos J, et al: Insulin is a key modulator of fetoplacental
endothelium metabolic disturbances in gestational diabetes
mellitus. Front Physiol. 7:1192016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Subiabre M, Silva L, Toledo F, Paublo M,
López MA, Boric MP and Sobrevia L: Insulin therapy and its
consequences for the mother, foetus, and newborn in gestational
diabetes mellitus. Biochim Biophys Acta Mol Basis Dis.
1864:2949–2956. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baumuller S, Lehnen H, Schmitz J, Fimmers
R and Müller AM: The impact of insulin treatment on the expression
of vascular endothelial cadherin and beta-catenin in human
fetoplacental vessels. Pediatr Dev Pathol. 18:17–23. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartakova V, Kollarova R, Kuricova K,
Sebekova K, Belobradkova J and Kankova K: Serum
carboxymethyl-lysine, a dominant advanced glycation end product, is
increased in women with gestational diabetes mellitus. Biomed Pap
Med Fac Univ Palacky Olomouc Czech Repub. 160:70–75. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Harsem NK, Braekke K, Torjussen T, Hanssen
K and Staff AC: Advanced glycation end products in pregnancies
complicated with diabetes mellitus or preeclampsia. Hypertens
Pregnancy. 27:374–386. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guosheng L, Hongmei S, Chuan N, Haiying L,
Xiaopeng Z and Xianqiong L: The relationship of serum AGE levels in
diabetic mothers with adverse fetal outcome. J Perinatol.
29:483–488. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stitt AW, Bhaduri T, McMullen CB, Gardiner
TA and Archer DB: Advanced glycation end products induce
blood-retinal barrier dysfunction in normoglycemic rats. Mol Cell
Biol Res Commun. 3:380–388. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guo XH, Huang QB, Chen B, Wang SY, Li Q,
Zhu YJ, Hou FF, Fu N, Brunk UT and Zhao M: Advanced glycation end
products induce actin rearrangement and subsequent
hyperpermeability of endothelial cells. APMIS. 114:874–883. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xie J, Mendez JD, Méndez-Valenzuela V and
Aguilar-Hernández MM: Cellular signalling of the receptor for
advanced glycation end products (RAGE). Cell Signal. 25:2185–2197.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Boulanger E, Grossin N, Wautier MP, Taamma
R and Wautier JL: Mesothelial RAGE activation by AGEs enhances VEGF
release and potentiates capillary tube formation. Kidney Int.
71:126–133. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rodger MA, Gris JC, de Vries JIP,
Martinelli I, Rey É, Schleussne E, Middeldorp S, Kaaja R, Langlois
NJ, Ramsay T, et al: Low-molecular-weight heparin and recurrent
placenta-mediated pregnancy complications: A meta-analysis of
individual patient data from randomised controlled trials. Lancet.
388:2629–2641. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wat JM, Hawrylyshyn K, Baczyk D, Greig IR
and Kingdom JC: Effects of glycol-split low molecular weight
heparin on placental, endothelial, and anti-inflammatory pathways
relevant to preeclampsia. Biol Reprod. 99:1082–1090. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gasowska K, Naumnik B, Klejna K and
Myśliwiec M: The influence of unfractionated and low-molecular
weight heparins on the properties of human umbilical vein
endothelial cells (HUVEC). Folia Histochem Cytobiol. 47:17–23.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kevane B, Egan K, Allen S, Maguire P,
Neary E, Lennon Á and Ní Áinle FN: Endothelial barrier protective
properties of low molecular weight heparin: A novel potential tool
in the prevention of cancer metastasis. Res Pract Thromb Haemost.
1:23–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Radu M and Chernoff J: An in vivo assay to
test blood vessel permeability. J Vis Exp. 73:e500622013.
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meng Q, Shao L, Luo X, Mu Y, Xu W, Gao C,
Gao L, Liu J and Cui Y: Ultrastructure of placenta of gravidas with
gestational diabetes mellitus. Obstet Gynecol Int. 2015:2831242015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hayward CE, Jones RL and Sibley CP:
Mechanisms of transfer across the human placenta. Placenta
Intrauterine Environment. 12:121–133. 2008.
|
|
25
|
Babawale MO, Lovat S, Mayhew TM, Lammiman
MJ, James DK and Leach L: Effects of gestational diabetes on
junctional adhesion molecules in human term placental vasculature.
Diabetologia. 43:1185–1196. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Y, Zhao HJ, Xia XR, Diao FY, Ma X,
Wang J, Gao L, Liu J, Gao C, Cui YG and Liu JY: Hypoxia-induced and
HIF1 a-VEGF-mediated tight junction dysfunction in choriocarcinoma
cells: Implications for preeclampsia. Clin Chim Acta. 489:203–211.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li S and Yang H: Relationship between
advanced glycation end products and gestational diabetes mellitus.
J Matern Fetal Neonatal Med. 32:2783–2789. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Holman RR, Paul SK, Bethel MA, Matthews DR
and Neil HA: 10-year follow-up of intensive glucose control in type
2 diabetes. New Engl J Med. 359:1577–1589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Antonetti DA, Lieth E, Barber AJ and
Gardner TW: Molecular mechanisms of vascular permeability in
diabetic retinopathy. Semin Ophthalmol. 14:240–248. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Singh R, Barden A, Mori T and Beilin L:
Advanced glycation end-products: A review. Diabetologia.
44:129–146. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chilelli NC, Burlina S and Lapolla A:
AGEs, rather than hyperglycemia, are responsible for microvascular
complications in diabetes: A ‘glycoxidation-centric’ point of view.
Nutr Metab Cardiovasc Dis. 23:913–919. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Svensjö E, Cyrino F, Michoud E, Ruggiero
D, Bouskela E and Wiernsperger N: Vascular permeability increase as
induced by histamine or bradykinin is enhanced by advanced
glycation endproducts (AGEs). J Diabetes Complications. 13:187–190.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wan W, Chen H and Li Y: The potential
mechanisms of Aβ-receptor for advanced glycation end-products
interaction disrupting tight junctions of the blood-brain barrier
in Alzheimer's disease. Int J Neurosci. 124:75–81. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schmidt AM, Yan SD, Yan SF and Stern DM:
The biology of the receptor for advanced glycation end products and
its ligands. Biochim Biophys Acta. 1498:99–111. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kisseleva T, Song L, Vorontchikhina M,
Feirt N, Kitajewski J and Schindler C: NF-kappaB regulation of
endothelial cell function during LPS-induced toxemia and cancer. J
Clin Invest. 116:2955–2963. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vandenbroucke E, Mehta D, Minshall R and
Malik AB: Regulation of endothelial junctional permeability. Ann N
Y Acad Sci. 1123:134–145. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Leach L, Gray C, Staton S, Babawale MO,
Gruchy A, Foster C, Mayhew TM and James DK: Vascular endothelial
cadherin and beta-catenin in human fetoplacental vessels of
pregnancies complicated by Type 1 diabetes: Associations with
angiogenesis and perturbed barrier function. Diabetologia.
47:695–709. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Obert E, Strauss R, Brandon C, Grek C,
Ghatnekar G, Gourdie R and Rohrer B: Targeting the tight junction
protein, zonula occludens-1, with the connexin43 mimetic peptide,
aCT1, reduces VEGF-dependent RPE pathophysiology. J Mol Med (Berl).
95:535–552. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Krishnasamy S, Ravi V, Rajaraman B, Kumar
Thulasingam S, Dhevasena CS, Pathak A, Swaminathan K, Sundaresan M,
Ayyappa KA, Arunkumar G, et al: Role of
VEGF165b/VEGFTOTAL ratio in gestational
diabetes mellitus. Gynecol Endocrinol. 35:811–814. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Melincovici CS, Boşca AB, Şuşman S,
Mărginean M, Mihu C, Istrate M, Moldovan IM, Roman AL and Mihu CM:
Vascular endothelial growth factor (VEGF)-key factor in normal and
pathological angiogenesis. Rom J Morphol Embryol. 59:455–467.
2018.PubMed/NCBI
|
|
41
|
Yan Y, Ji Y, Su N, Mei X, Wang Y, Du S,
Zhu W, Zhang C, Lu Y and Xing XH: Non-anticoagulant effects of low
molecular weight heparins in inflammatory disorders: A review.
Carbohydr Polym. 160:71–81. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Abdel-Salam OM, Baiuomy AR, Ameen A and
Hassan NS: A study of unfractionated and low molecular weight
heparins in a model of cholestatic liver injury in the rat.
Pharmacol Res. 51:59–67. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nagy Z, Turcsik V and Blaskó G: The effect
of LMWH (Nadroparin) on tumor progression. Pathol Oncol Res.
15:689–692. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yalniz M, Demirel U, Orhan C, Bahcecioglu
IH, Ozercan IH, Aygun C, Tuzcu M and Sahin K: Nadroparin sodium
activates Nrf2/HO-1 pathway in acetic acid-induced colitis in rats.
Inflammation. 35:1213–1221. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Delézay O, Hé Z, Sabido O, Hodin S, Bin V,
Saleem MA, Mismetti P and Delavenne X: Effects of heparin and
derivatives on podocytes: An in vitro functional and morphological
evaluation. J Cell Physiol. Jan 26–2019.doi: 10.1002/jcp.28191
(Epub ahead of print). View Article : Google Scholar
|
|
46
|
Bentzer P, Fisher J, Kong HJ, Mörgelin M,
Boyd JH, Walley KR, Russell JA and Linder A: Heparin-binding
protein is important for vascular leak in sepsis. Intensive Care
Med Exp. 4:332016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Takeuchi A, Yamamoto Y, Munesue S,
Harashima A, Watanabe T, Yonekura H, Yamamoto H and Tsuchiya H: Low
molecular weight heparin suppresses receptor for advanced glycation
end products-mediated expression of malignant phenotype in human
fibrosarcoma cells. Cancer Sci. 104:740–749. 2013. View Article : Google Scholar : PubMed/NCBI
|
